NDATOPICALSOLUTIONPriority Review
Approved
Aug 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALOTEX (haloprogin) is a topical antifungal solution approved in 1971 for the treatment of fungal skin infections. The drug is a small-molecule antifungal agent administered as a topical solution directly to affected skin areas. It represents a legacy dermatology product from Bristol Myers Squibb's portfolio.
LOE Approaching
As a legacy product approaching LOE with no active clinical development, commercial teams are minimal and focused on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HALOTEX offers minimal career growth potential given its LOE-approaching status and zero linked job openings. Career development would be constrained to maintaining compliance and managing product runoff rather than building commercial or clinical expertise.
Regulatory AffairsProduct Manager (Maintenance)
Worked on HALOTEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.